Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication Fluticasone Propionate HFA is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients aged 4 years and older. Limitations of Use Fluticasone Propionate HFA is not indicated for the relief of acute bronchospasm. FDA label
Also known as FLOVENT (fluticasone propionate) HFA
FLOVENT HFA · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Subjects receiving HFA | EXPERIMENTAL | Subjects in Session 1 will receive two inhalations of placebo HFA by meter-dose inhaler (MDI) twice daily and in Session 2 subjects will receive two inhalations of fluticasone propionate (FP) HFA MDI 44 mcg twice daily |
| Name | Type | Description |
|---|---|---|
| FLOVENT (fluticasone propionate) HFA | DRUG | FLOVENT HFA consists of a white to off-white suspension of FP (micronized) in a liquefied hydrofluoroalkane propellant, 1,1,1,2-tetrafluoroethane. Subject will receive FP HFA using an Aerochamber Plus with Infant Mask. |
| Placebo HFA | DRUG | Subjects will receive FP-matched placebo using an Aerochamber Plus with Infant Mask. |
Inclusion Criteria: * Subjects who have experienced 2 or more wheezing episodes in the previous 6 months. * Subjects may not have taken any corticosteroids in the 4 weeks prior to dosing * Parents/guardians should be able to read and comprehend diary information collected throughout the study * Par...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
FLOVENT HFA is used for asthma. It is an inhaled small molecule therapy developed by GSK plc, traded as GSK, and studied in a Phase 1 trial in the United States. The trial enrolled 16 subjects aged 6 to 12 months with asthma.
FLOVENT HFA is made by GSK plc, which trades under the ticker GSK. GSK developed and studied the drug in a Phase 1 clinical trial in the United States. The trial, NCT00370097, was completed and enrolled 16 subjects.
FLOVENT HFA is in Phase 1 clinical development. Its single trial, NCT00370097, was a completed Phase 1 study in the United States that enrolled 16 subjects aged 6 to 12 months with asthma. No active trials are ongoing.
FLOVENT HFA has been studied in one clinical trial, NCT00370097, titled FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects. The Phase 1 trial was completed, enrolled 16 subjects with asthma, and took place in the United States.
Yes, FLOVENT HFA is also known as FLOVENT (fluticasone propionate) HFA. Both names refer to the same inhaled asthma therapy developed by GSK plc, ticker GSK, which was studied in the completed Phase 1 trial NCT00370097.